Updated: Roche hits the brakes on Alzheimer's trials after resurrected drug flunks PhIII
Is it finally time for Roche to give up on gantenerumab?
The Swiss pharma giant revealed that the anti-amyloid drug has failed two Phase III trials in early Alzheimer’s disease, the latest in a streak of negative readouts for gantenerumab. Not only did it miss the primary endpoints of slowing clinical decline, the level of beta-amyloid removal was also lower than expected.
In the wake of the flop, Roche’s Genentech subsidiary is hitting the brakes on SKYLINE, a separate Phase III trial that kicked off in March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.